Penumbra Inc

Financials

Activos totales 822.98 M1.24 B1.37 B1.56 B1.53 B1.83 B Total de pasivos 185.19 M290.32 M372.03 M377.36 M382.25 M398.92 M Capital total 637.79 M953.93 M998.86 M1.18 B1.15 B1.43 B Total de pasivos y patrimonio neto 822.98 M1.24 B1.37 B1.56 B1.53 B1.83 B Deuda total —————— Deuda neta ——————

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm. In January 2026, Boston Scientific announced it would acquire Penumbra in a $15 billion cash and stock deal. The deal was expected to close by yearend.

PEN

Financials

Penumbra Inc

Noticias

Ensayo de Penumbra muestra mejores resultados para embolia pulmonar

3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN)

Harpreet Grewal, director de Penumbra, vende acciones por 32.822 dólares

Penumbra (PEN) Down 1.6% Since Last Earnings Report: Can It Rebound?

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Beats Revenue Estimates

UBS reitera calificación de Penumbra con confianza en trombectomía

UBS reiterates Penumbra stock rating on thrombectomy confidence

Fewer Deals, Bigger Stakes: Deciphering The 2026 M&A Landscape And The Rise Of Megadeals

PEN Stock Up Following Q4 Earnings & Revenue Beat, Margins Rise

UBS reitera calificación Neutral para Penumbra con precio objetivo de 374 dólares

UBS reitera calificación Neutral en Penumbra con precio objetivo de $374